ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ZL-1503

A development code.

Its studies are mostly in Dermatitis, Atopic, led by Zai Lab.

Furthest: phase 1, since Nov 14, 20252 company-led studies, 2 open or runningNext primary completion: Feb 6, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zai Lab22 open or runningphase 1since Nov 14, 2025Nov 14, 2025Feb 6, 2027phase 1 · NCT07658482

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First study: phase 1 study in Dermatitis, AtopicFirst studyNCT07235384 · 84 planned · Australia, China, New Zealand
  2. Jun 10, 2026Phase 1 study in Healthy VolunteersNCT07658482 · 36 planned · New Zealand

Ahead

  1. Feb 6, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07658482
  2. Dec 28, 2027Primary completion: phase 1 study in Dermatitis, AtopicNCT07235384

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07658482Healthy Volunteers · New Zealand1Not yet recruitingFeb 6, 202736
NCT07235384Dermatitis, Atopic · Australia, China, New Zealand1RecruitingDec 28, 202784

How it is read

Names in the registry

  • “ZL-1503”, 5 entries

Codes read as this program: ZL1503.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.